<bill session="114" type="h" number="6033" updated="2018-11-21T21:23:45Z">
  <state datetime="2016-09-14">REFERRED</state>
  <status>
    <introduced datetime="2016-09-14"/>
  </status>
  <introduced datetime="2016-09-14"/>
  <titles>
    <title type="short" as="introduced">Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</title>
    <title type="official" as="introduced">To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.</title>
    <title type="display">Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act</title>
  </titles>
  <sponsor bioguide_id="P000608"/>
  <cosponsors>
    <cosponsor bioguide_id="B001296" joined="2016-09-14"/>
    <cosponsor bioguide_id="R000598" joined="2016-09-14"/>
  </cosponsors>
  <actions>
    <action datetime="2016-09-14">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-09-14" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Infectious and parasitic diseases"/>
  </subjects>
  <amendments/>
  <summary date="2016-09-14T04:00:00Z" status="Introduced in House">Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)</summary>
  <committee-reports/>
</bill>
